The Weight-Loss Drug Wave: Which ETFs Are Positioned to Cash In?

The obesity drug boom is reshaping the investment landscape, and savvy investors are looking beyond the headlines. While celebrities like Oprah champion medications like Wegovy and Ozempic, the real opportunity lies in identifying which exchange-traded funds (ETFs) can genuinely capitalize on this healthcare trend.

What’s driving this shift? Prescription weight-loss medications have moved from niche treatments to mainstream conversation. Novo Nordisk’s semaglutide (marketed as Wegovy for obesity and Ozempic for diabetes) and Eli Lilly’s tirzepatide (Mounjaro) are generating unprecedented demand. But here’s the thing: betting on this trend isn’t just about the drugs themselves—it’s about understanding the entire ecosystem of companies benefiting from the weight management revolution.

Healthcare Giants Leading the Charge: iShares US Healthcare Providers ETF (IHF)

The iShares US Healthcare Providers ETF (IHF) has climbed 11% over the past year, making it one of the more resilient plays in the healthcare sector. With a lean expense ratio of 0.40%, this fund tracks the Dow Jones U.S. Select Health Care Providers Index and focuses on healthcare delivery infrastructure rather than just pharma.

What’s compelling here is the composition. The fund’s top holdings—UnitedHealth Group (22%), Cigna (10%), CVS Health (4%), and Humana (4%)—all offer integrated weight management solutions. UnitedHealth’s Optum division provides comprehensive wellness programs, while Humana integrates diet plans into their offerings. CVS MinuteClinics stock over-the-counter supplements, and Cigna provides nutritional counseling. These aren’t flashy plays, but they’re defensive and steady.

The fund shows a beta of 0.72, indicating lower volatility compared to the broader market. With a 0.78% dividend yield and a recent five-to-one stock split that improved accessibility, IHF appeals to investors seeking stability during the healthcare boom.

Pure-Play Obesity Exposure: The Obesity ETF (SLIM)

For those wanting direct obesity etf exposure, The Obesity ETF (SLIM) takes a more specialized approach. This Janus Henderson fund invests at least 80% of assets in companies across the entire obesity treatment spectrum—pharmaceuticals, medical devices, weight-loss programs, and even specialized apparel.

The concentration strategy matters here. Novo Nordisk represents 20% of holdings, while DexCom makes up 13%. This means SLIM is betting heavily on the companies literally making the drugs and monitoring tools that enable weight management. Herbalife (NYSE: HLF), another major holding, rounds out the portfolio with its portfolio of nutritional products.

Related companies like Tandem Diabetes Care (TNDM), Insulet Corporation (PODD), and DexCom provide crucial support infrastructure—continuous glucose monitors and insulin pumps that complement the newer weight-loss medications. Together, they make managing metabolic health more accessible.

However, there’s a reality check: SLIM has posted a year-to-date loss of 11.27%, reflecting the unpredictability of specialized healthcare funds. With a net asset value of $11.63 million and a 0.57% dividend yield, this is a concentrated bet that requires conviction.

Pharma’s Ascendancy: VanEck Pharmaceutical ETF (PPH)

VanEck Pharmaceutical ETF (PPH) has gained more than 7% over the past year to reach $85.44, making it the clearest beneficiary of the weight-loss drug surge. With net assets of $543.2 million and an impressively low 0.36% expense ratio, this fund captures broad pharmaceutical exposure while disproportionately benefiting from the obesity treatment revolution.

The key holdings tell the story. Eli Lilly has emerged as the weight-loss pharmaceutical heavyweight thanks to tirzepatide (Mounjaro), which can reduce weight by up to 20% in non-diabetics. Originally approved for type 2 diabetes, Mounjaro works by blocking GLP-1 and GIP receptors to regulate hunger and insulin secretion.

Novo Nordisk’s semaglutide franchise—split between Wegovy (obesity) and Ozempic (diabetes)—has demonstrated 15% weight loss in clinical settings, driving adoption rates that exceed supply. These aren’t incremental improvements; they’re genuine breakthroughs reshaping how we approach chronic weight management.

The Real Play

The obesity etf landscape offers three distinct entry points depending on your risk tolerance. Want stability? IHF provides healthcare infrastructure exposure. Seeking pure-play concentration? SLIM delivers direct obesity treatment exposure. Need broad pharma participation? PPH captures the entire upside.

The underlying trend is undeniable: weight-loss medications are transitioning from experimental treatments to standard of care. Whether through diversified healthcare providers, specialized obesity funds, or traditional pharma ETFs, investors have multiple pathways to participate in this structural shift. The question isn’t whether this market exists—it clearly does—but which vehicle best matches your portfolio strategy.